



4950 Research Park Way
Lawrence, KS 66047
Tel: 785-838-3767
Fax: 785-838-3747

March 24, 2008

**deCODE biostructures Renews Collaboration with Deciphera
Pharmaceuticals, LLC.**

LAWRENCE,KS deCODE biostructures, Inc., (www.decodechembio.com) announces the renewal of its research agreement with Deciphera Pharmaceuticals, LLC (www.deciphera.com) to collaborate for a fifth year since the initiation of the relationship. Under the terms of the agreement, deCODE biostructures will continue to perform gene-to-structure research for Deciphera on multiple kinase targets. Financial terms were not disclosed. The collaboration provides Deciphera with access to deCODE's expertise in protein-ligand co-structure determination, from the engineering of synthetic kinase genes to the determination of high resolution kinase-ligand co-crystal structures.

About Deciphera Pharmaceuticals. Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce "best-in-class" small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. Deciphera's kinase inhibitors target the mechanisms that render kinases oncogenic, retain potency against gatekeeper mutations, and afford selectivity profiles not easily attained by other approaches. For more information, visit the Company's website at www.deciphera.com.
